Back to Search
Start Over
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
- Source :
-
PloS one [PLoS One] 2008 Jul 09; Vol. 3 (7), pp. e2636. Date of Electronic Publication: 2008 Jul 09. - Publication Year :
- 2008
-
Abstract
- Background: Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion.<br />Methodology/principal Findings: The trial was conducted at The Johns Hopkins Center for Immunization Research, Washington DC, USA, between May 16, 2005-April 30, 2007. The trial was designed to enroll 72 healthy male and non-pregnant female volunteers into 1 group to receive adjuvant control and 6 groups to receive escalating doses of the vaccines. Due to unexpected reactogenicity, the vaccination was halted and only 36 volunteers were enrolled into 4 groups: 3 groups of 10 volunteers each were immunized with 5 microg of Pfs25/ISA 51, 5 microg of Pvs25/ISA 51, or 20 microg of Pvs25/ISA 51, respectively. A fourth group of 6 volunteers received adjuvant control (PBS/ISA 51). Frequent local reactogenicity was observed. Systemic adverse events included two cases of erythema nodosum considered to be probably related to the combination of the antigen and the adjuvant. Significant antibody responses were detected in volunteers who completed the lowest scheduled doses of Pfs25/ISA 51. Serum anti-Pfs25 levels correlated with transmission blocking activity.<br />Conclusion/significance: It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development. This is the first report that the formulation is associated with systemic adverse events including erythema nodosum.<br />Trial Registration: ClinicalTrials.gov NCT00295581.
- Subjects :
- Adolescent
Adult
Animals
Antigens, Protozoan chemistry
Antigens, Surface chemistry
Disease Transmission, Infectious
Female
Humans
Malaria Vaccines chemistry
Malaria, Falciparum prevention & control
Malaria, Falciparum transmission
Malaria, Vivax prevention & control
Malaria, Vivax transmission
Male
Mannitol administration & dosage
Mannitol chemistry
Middle Aged
Oleic Acids chemistry
Plasmodium falciparum immunology
Plasmodium vivax immunology
Protozoan Proteins chemistry
Vaccines, Synthetic administration & dosage
Vaccines, Synthetic chemistry
Antigens, Protozoan immunology
Antigens, Surface immunology
Malaria Vaccines adverse effects
Malaria Vaccines immunology
Mannitol analogs & derivatives
Oleic Acids administration & dosage
Protozoan Proteins adverse effects
Protozoan Proteins immunology
Recombinant Proteins adverse effects
Recombinant Proteins immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 3
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 18612426
- Full Text :
- https://doi.org/10.1371/journal.pone.0002636